Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.34
+1.78 (0.85%)
AAPL  273.84
+1.70 (0.62%)
AMD  213.84
+0.00 (0.00%)
BAC  51.65
+1.24 (2.46%)
GOOG  312.07
+1.15 (0.37%)
META  651.24
+11.94 (1.87%)
MSFT  389.00
+0.00 (0.00%)
NVDA  197.00
+4.15 (2.15%)
ORCL  148.49
+2.35 (1.61%)
TSLA  415.19
+5.81 (1.42%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.